Diabetic Foot Ulcer Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2030

The global diabetic foot ulcer treatment market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The demand for diabetic foot ulcer treatment is primarily being boosted owing to key factors such as the increasing prevalence of diabetic foot ulcers, increasing risk factors such as diabetes, and others associated with the development of diabetic foot ulcers, the growing technological advancements along with research and development activities, among other factors are expected to create a positive impact on the market growth during the forecast period from 2024-2030.

Diabetic Foot Ulcer Treatment Market Dynamics:

According to the World Health Organization 2021, in the year 2020, the prevalence of foot ulcers among patients suffering from diabetes was observed to be 3% to 13% globally. Also, as per the source Wounds Asia 2021, globally there is an amputation that is observed every 30 seconds owing to the non-healing diabetic foot ulcers and the 5-year mortality rate following amputations can be observed to be about 40%-70%. Owing to a rise in the number of patients affected by diabetic foot ulcers, there will be an increase in the demand for diabetic foot ulcer treatments in the upcoming years.

Lifestyle-related disorders such as diabetes is the primary risk factor associated with the development of diabetic foot ulcers. For example, as per data published by the International Diabetes Federation 2021, globally around 537 million adults aged between 20 and 79 years have diabetes and this number is estimated to rise to 643 million by 2030 and 783 million by 2045.

Thus, all the above-stated facts and figures for the total number of diabetic foot ulcers and diabetes shall increase the market demand for their treatments, thus positively impacting the market growth for diabetic foot ulcer treatment during the forecast period from 2023-2028.

The increasing product development activities for diabetic foot ulcer treatment are further expected to aid in the growth of the global diabetic foot ulcer treatment market. For instance, in October 2022, Healthium Medtech announced the launch of a new wound dressing portfolio Theruptor Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers.

However, the high costs associated with advanced wound care devices and treatments for diabetic foot ulcers, and lack of reimbursement policies, among others may act as barriers to the diabetic foot ulcer treatment market growth.

The COVID-19 pandemic had a negative impact on the overall market growth of diabetic foot ulcer treatment as the majority of the healthcare industry was dealing with the issue of the COVID-19 pandemic, and the COVID-19 affected patients were among the primary class of people who were adhered first. But owing to severe lockdowns and restrictions imposed to control the spread of the coronavirus infections, the movement and active lifestyle of people was severely impacted due to which they faced many health complications including obesity and diabetes which may increase the risk of getting affected with diabetic foot ulcers in future. Nevertheless, the post-pandemic arena is going to be uplifting for the diabetic foot ulcer market owing to the resumption of activities in the healthcare and the pharmaceutical industry, the opening up of lockdowns in various countries, and vaccine immunizations. Also, due to an alarming demand for diabetic foot ulcer treatments after the COVID-19 pandemic and in times to come, the market for diabetic foot ulcer treatment is expected to further grow in the upcoming years.

Diabetic Foot Ulcer Treatment Market Segment Analysis:

Diabetic Foot Ulcer Treatment Market by Treatment Type (Wound Care [Foams and Dressings, Gels, Creams, and Others], Therapy Devices [Negative Pressure Wound Therapy (NPWT) and Extracorporeal Shock Wave Therapy (ESWT)], and Therapeutics), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment type segment of the diabetic foot ulcer treatment market, the therapeutics category is expected to amass a significant revenue share in the year 2023. This can be attributed to the large number of advantages associated with the drugs prescribed for diabetic foot ulcers including long-lasting and permanent treatment as compared to other types of treatment, along with the increasing product development activities such as product launches in the therapeutics category during the given forecast period.

The patient may be prescribed antibiotics, anti-platelets, or anticlotting medications for the treatment of diabetic foot ulcers if the infection progresses even after preventive or anti-pressure treatments. Many of these antibiotics attack Staphylococcus aureus, bacteria known to cause staph infections, or beta-hemolytic Streptococcus, which is normally found in one’s intestines. The aforementioned factors cannot be done by assist systems for foot ulcers such as bandages, dressings and by gels, creams, and others.

Along with this, the growing focus of manufacturers on developing and manufacturing new drugs for diabetic foot ulcers is going to accelerate the demand for the same. For example, in September 2020, Centaur Pharmaceuticals announced the launch of a New Chemical Entity (NCE)- WOXheal globally, having a dual mechanism of action, i.e., having a functional antibacterial action against gram-positive and gram-negative bacteria. It also promotes the growth of fibroblast cells, thereby yielding complete wound closure.

Therefore, the benefits associated with therapeutic drugs along with product launches would increase the demand for therapeutics in the market, which will drive the growth of the overall diabetic foot ulcer treatment market during the forecast period.

North America is expected to dominate the overall Diabetic Foot Ulcer Treatment Market:

Among all the regions, North America is estimated to account for the largest share of the Diabetic Foot Ulcer Treatment market in the year 2023. This domination is due to factors such as the presence of a large patient population base associated with diabetic foot ulcers, and its risk factors such as diabetes, rising research and development activities in the region, and surging awareness programs, among others are also driving the market growth of diabetic foot ulcer treatment in North America.

According to the Centers for Disease Control and Prevention (CDC) 2021, in 2020, diabetes was considered to be one of the leading causes of non-traumatic lower extremity amputations in the United States, with approximately 5% of diabetics developing foot ulcers.

In another report by the CDC’s National Diabetes Statistics Report for 2022, cases of diabetes had risen to an estimated 37.3 million. Uncontrollable diabetes often leads to the development of ulcers known as diabetic wounds. Thus, the high burden of diabetic people in the region susceptible to developing foot ulcers will thereby increase the demand for diabetic foot ulcer treatment devices and therapeutics in the North America region.

The rising number of awareness programs is further expected to drive the demand for diabetic foot ulcer treatment in the region. For instance, Healogics, LLC promoted a campaign in November 2022 in the United States to raise awareness of diabetes and the wounds associated with it. American wound care facilities educated the general public about diabetes and chronic wounds associated with the disease, such as diabetic foot ulcers, during this campaign.

Therefore, the interplay of all the above-mentioned factors is expected to drive the market growth for diabetic foot ulcer treatment in the region during the forecast period from 2024-2030.

Diabetic Foot Ulcer Treatment Market Key Players:

Some of the key market players operating in the diabetic foot ulcer treatment market include 3M, Smith+Nephew, Convatec Inc., Coloplast Corp, Integra LifeSciences, Cardinal Health, TISSUE REGENIX WOUND CARE INC., B. Braun SE, Organogenesis Inc., Medline Industries, Inc., SIGVARIS GROUP, Osiris Therapeutics Inc., MiMedx, LifeNet Health, Axio Biosolutions Pvt Ltd, and others.

Recent Developmental Activities in the Diabetic Foot Ulcer Treatment Market:

• In October 2022, Healthium Medtech, a global medical devices company focused on surgical, post-surgical, and chronic care, launched a new wound dressing portfolio Theruptor Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers.
• In November 2021, Paracrine, Inc. announced that the FDA granted full approval of its Investigational Device Exemption (IDE) to conduct a new pivotal trial titled Adipose-Derived Regenerative Cells (ADRCs) in the Treatment of Diabetic Foot Ulcers (DFUs): A Prospective, Double-blind, Multi-center, Randomized, Parallel-group Study - The “ASCEND Trial.”
• In February 2021, Integrated Woundcare Company, Axio Biosolutions announced that it received European CE Certification from DNV GL Norway for its next-generation advanced wound care product range, MaxioCel, based on Bioactive Microfiber Gelling technology that accelerates healing through quicker granulation.

Key Takeaways from the Diabetic Foot Ulcer Treatment Market Report Study

• Market size analysis for current diabetic foot ulcer treatment market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global diabetic foot ulcer treatment market.
• Various opportunities available for the other competitor in the diabetic foot ulcer treatment market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current diabetic foot ulcer treatment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for diabetic foot ulcer treatment market growth in the coming future?

Target Audience who can be benefited from this Diabetic Foot Ulcer Treatment Market Report Study

• Diabetic foot ulcer treatment products providers
• Research organizations and consulting companies
• Diabetic foot ulcer treatment-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in diabetic foot ulcer treatment
• Various end-users who want to know more about the diabetic foot ulcer treatment market and the latest technological developments in the diabetic foot ulcer treatment market.

Frequently Asked Questions for the Diabetic Foot Ulcer Treatment Market:

1. What are Diabetic foot ulcers?

A diabetic foot ulcer is an open sore or wound that occurs in approximately 15 percent of patients with diabetes and is commonly located on the bottom of the foot. Anyone who has diabetes can develop a foot ulcer. People who use insulin are at a higher risk of developing a foot ulcer, as are patients with diabetes-related kidney, eye, and heart disease. Being overweight and using alcohol and tobacco also play a role in the development of foot ulcers.

2. What is the market for Global Diabetic Foot Ulcer Treatment?

The global diabetic foot ulcer treatment market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Diabetic Foot Ulcer Treatment market?

The demand for diabetic foot ulcer treatment is primarily being boosted owing to key factors such as the increasing prevalence of diabetic foot ulcers, increasing risk factors such as diabetes, the growing technological advancements along with research and development activities, among other factors that are expected to create a positive impact on the market growth during the forecast period from 2024-2030.

4. Who are the key players operating in the global Diabetic Foot Ulcer Treatment market?

Some of the key market players operating in the diabetic foot ulcer treatment market include 3M, Smith+Nephew, Convatec Inc., Coloplast Corp, Integra LifeSciences, Cardinal Health, TISSUE REGENIX WOUND CARE INC., B. Braun SE, Organogenesis Inc., Medline Industries, Inc., SIGVARIS GROUP, Osiris Therapeutics Inc., MiMedx, LifeNet Health, Axio Biosolutions Pvt Ltd, and others.

5. Which region has the highest share in the Diabetic Foot Ulcer Treatment market?

North America is expected to dominate the overall diabetic foot ulcer treatment market during the forecast period from 2024-2030. This domination is due to factors such as the presence of a large patient population base associated with diabetic foot ulcers, and its risk factors such as diabetes, rising research and development activities in the region, and surging awareness programs, among others are also driving the market growth of diabetic foot ulcer treatment in North America.


This product will be delivered within 2 business days.